Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05053659Phase 1Active, not recruiting
- Start
- Jun 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loncastuximab tesirine and venetoclax in non-Hodgkin lymphoma (NHL). Primary endpoints: Dose Limiting Toxicities and Maximum Tolerated Dose at 6 weeks. Started Jun 2022; status: active, not recruiting.
02
Drugs
loncastuximab tesirinevenetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05053659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053659.